Opus Genetics, Inc.
Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024. In the quarter to June 2026, revenue fell 73.8%, EPS grew 33.3% and free cash flow fell 16.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IRD
Opus Genetics, Inc. (IRD) EV/Sales
As of 16 October 2026, Opus Genetics, Inc. (IRD) trades at a EV/Sales of 31.5×. Over the past ten years it has ranged from −1.8× (December 2024) to 53.4× (September 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.7× | 3,578.66% |
| FY2024 | 0.2× | (81.48%) |
| FY2023 | 0.8× | 23.50% |
| FY2022 | 0.7× | (96.21%) |
| FY2021 | 17.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 34.4× | 22.34% |
| Mar 2026 | 28.1× | 390.85% |
| Dec 2025 | 5.7× | (3.75%) |
| Sep 2025 | 5.9× | 223.37% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| CCCC C4 Therapeutics, Inc. compare | 3.6× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.1× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| IRD Opus Genetics, Inc. | 31.5× |
| CYPH Cypherpunk Technologies Inc. compare | 311× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)